The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.

Journal: Journal of managed care & specialty pharmacy
PMID: 29290168

Abstract

BACKGROUND: Anticitrullinated protein antibodies (ACPAs) are serological biomarkers associated with early, rapidly progressing rheumatoid arthritis (RA), including more severe disease and joint damage. ACPA testing has become a routine tool for RA diagnosis and prognosis. Furthermore, treatment efficacy has been shown to vary by ACPA-positive status. However, it is not clear if the economic burden of patients with RA varies by ACPA status.

Authors

  • Jason Shafrin
    1 Precision Health Economics, Los Angeles, California.
  • Mahlet Gizaw Tebeka
    1 Precision Health Economics, Los Angeles, California.
  • Kwanza Price
    2 Bristol-Myers Squibb, Princeton Pike, New Jersey.
  • Chad Patel
    2 Bristol-Myers Squibb, Princeton Pike, New Jersey.
  • Kaleb Michaud
    3 University of Nebraska Medical Center, Omaha, and National Data Bank for Rheumatic Diseases, Wichita, Kansas.

Keywords

External Resources

Popular Topics
Recent Journals